T1	intervention 0 11	Dexrazoxane
T2	condition 63 98	chemotherapy-induced cardiotoxicity
T3	eligibility 194 254	breast cancer with concurrent type 2 diabetes mellitus (DM2)
T4	No-of-participants 256 262	Eighty
T5	control 341 358	chemotherapy only
T6	outcome 865 902	baseline systole or diastole function
T7	outcome-Measure 749 765	Cardiac function
T8	outcome-Measure 770 780	hematology
T9	outcome 993 1017	greater reductions in Ea
T10	outcome 1036 1076	greater elevations in E/Ea and Tei index
T11	outcome 1158 1178	superoxide dismutase
T12	outcome 1210 1237	serum malondialdehyde (MDA)
T13	outcome 1288 1321	Serum superoxide dismutase levels
T14	outcome 1359 1388	before and after chemotherapy
T15	outcome 1438 1457	before chemotherapy
T16	outcome 1467 1476	serum MDA
T17	outcome 1502 1520	after chemotherapy
